Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 8:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 4,251 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blood samples collected Clear all
Recruiting Phase 2 Interventional

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

NCT07112053
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
Interventions
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Capecitabine, Computed Tomography, Cyclin-Dependent Kinase 4 Inhibitor, Cyclin-Dependent Kinase 6 Inhibitor, F-18 16 Alpha-Fluoroestradiol, Hormone Therapy, Positron Emission Tomography, Biopsy Procedure, Biospecimen Collection, Abemaciclib
Biological · Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 11, 2026, 8:01 AM EDT
Completed Not applicable Interventional

Next Generation Sequence Target-Directed Therapy in Treating Patients With Cancer

NCT02132845
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
cytology specimen collection procedure, targeted therapy, therapeutic procedure, laboratory biomarker analysis
Other · Drug · Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 11, 2026, 8:01 AM EDT
Active, not recruiting No phase listed Observational

Correlating MicroRNA Changes With Sepsis Outcomes

NCT03929159
View directory record Official record
Conditions
Septicemia
Interventions
Biospecimen Collection
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 11, 2026, 8:01 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Histamine as a Molecular Transducer of Adaptation to Exercise

NCT05206227
View directory record Official record
Conditions
Postexercise Hypotension
Interventions
Aerobic Exercise, alpha-FMH, Resistance and Aerobic Exercise, Antihistamine
Behavioral · Drug
Lead sponsor
University of Oregon
Other
Eligibility
18 Years to 40 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 11, 2026, 8:01 AM EDT
Completed Not applicable Interventional Results available

Effects of Administration of SCFA in Rheumatoid Arthritis Inadequate Responders

NCT05718583
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Butyrate
Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 11, 2026, 8:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Expression of IFN-epsilon in the Female Reproductive Tract

NCT02416154
View directory record Official record
Conditions
Interferon Expression in the Female Reproductive Tract
Interventions
Reproductive tract and blood sampling
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 27, 2021 · Synced Oct 11, 2026, 8:01 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate

NCT01934842
View directory record Official record
Conditions
Diabetes, Anemia
Interventions
TAP20-C, SAFE-T-FILL
Device
Lead sponsor
Seventh Sense Biosystems
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Oct 11, 2026, 8:01 AM EDT
Completed No phase listed Observational

The Effect of the Microbiome on Immune Checkpoint Inhibitor Response in Melanoma Patients

NCT05102773
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Laboratory Biomarker Analysis, Questionnaire Administration
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 11, 2026, 8:01 AM EDT
Terminated Phase 2 Interventional Results available

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

NCT01746173
View directory record Official record
Conditions
T-cell Non-Hodgkin Lymphoma
Interventions
Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, Prednisone, Filgrastim, Plerixafor, Stem Cell Collection, Palifermin, Gemcitabine, Busulfan, Melphalan, Stem Cell Transplant
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 11, 2026, 8:01 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Chronic Cannabis Smoking, Oxidative Stress and the Pulmonary Innate Immune Response

NCT02480283
View directory record Official record
Conditions
Cannabis Smoking, Oxidative Stress
Interventions
Bronchoscopy, Chest X-ray, Venipuncture, Intravenous Catheter
Procedure · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Oct 11, 2026, 8:01 AM EDT
Recruiting No phase listed Observational

PRecision Integrated Saturation Monitor

NCT07686341
View directory record Official record
Conditions
CHD - Congenital Heart Disease, Single Ventricle Heart Disease
Interventions
vital sign monitoring
Device
Lead sponsor
Le Bonheur Children's Hospital
Other
Eligibility
0 Months to 12 Months
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 11, 2026, 8:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally

NCT01575405
View directory record Official record
Conditions
HIV Prevention
Interventions
Rectal formulation (RF) of tenofovir 1% gel, Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel, Universal HEC Placebo Gel Formulation
Drug
Lead sponsor
Ian McGowan
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
Los Angeles, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Oct 11, 2026, 8:01 AM EDT
Completed No phase listed Observational

Changes in Cytokine Levels During an Acute Exacerbation of Chronic Obstructive Pulmonary Disease

NCT00281242
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive
Interventions
blood draw
Other
Lead sponsor
University of Michigan
Other
Eligibility
40 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 11, 2026, 8:01 AM EDT
Terminated Phase 1 Interventional Results available

Single Dose Pravastatin Pharmacokinetics in Pediatric Peritoneal Dialysis Patients

NCT00571194
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
pravastatin
Drug
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
12 Months to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 11, 2026, 8:01 AM EDT
Completed No phase listed Observational

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

NCT00900302
View directory record Official record
Conditions
Cancer
Interventions
protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
Genetic · Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 120 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 10, 2016 · Synced Oct 11, 2026, 8:01 AM EDT
Active, not recruiting Phase 1 Interventional

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

NCT05627245
View directory record Official record
Conditions
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Follicular Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory Follicular Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
Interventions
Belinostat, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Pharmacokinetic Study, Positron Emission Tomography and Computed Tomography Scan, Tazemetostat
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
11
States / cities
Sacramento, California • New Haven, Connecticut • Fairway, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 11, 2026, 8:01 AM EDT
Completed Not applicable Interventional

A One Visit Follow Up of Adults With Fabry Disease Who Started Long-term Enzyme Replacement Therapy As Children

NCT04002531
View directory record Official record
Conditions
Quality of Life, Renal Insufficiency, Cardiac Event
Interventions
General and Neurological examination, Vital signs, 12 lead electrocardiogram, Echocardiogram, Blood draw, Urine collection, 2-hour Holter Monitor, Brief Pain Inventory questionnaire, Quality of Life questionnaire
Other · Procedure
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 11, 2026, 8:01 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers Results available

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

NCT02003222
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Leucovorin Calcium, Lumbar Puncture, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate, X-Ray Imaging
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
30 Years to 70 Years
Enrollment
488 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
531
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 328 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 11, 2026, 8:01 AM EDT
Recruiting Phase 1 Interventional

Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer

NCT07645651
View directory record Official record
Conditions
Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
Interventions
Samuraciclib, Computed Tomography, Endoscopic Ultrasound Biopsy, Biospecimen Collection
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 11, 2026, 8:01 AM EDT
Active, not recruiting No phase listed Observational

A Study of miRNA 371 in Patients With Germ Cell Tumors

NCT04435756
View directory record Official record
Conditions
Germ Cell Tumor, Metachronous Malignant Neoplasm, Seminoma, Stage I Testicular Cancer AJCC v8, Stage IA Testicular Cancer AJCC v8, Stage IB Testicular Cancer AJCC v8, Stage IS Testicular Cancer AJCC v8
Interventions
Biomarker Analysis, Blood Product Collection
Other · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
412
States / cities
Gilbert, Arizona • Kingman, Arizona • Tucson, Arizona + 261 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 11, 2026, 8:01 AM EDT
Active, not recruiting Phase 2 Interventional

Cabozantinib in High Grade Neuroendocrine Neoplasms

NCT04412629
View directory record Official record
Conditions
High Grade Neuroendocrine Neoplasms
Interventions
Cabozantinib, Blood for plasma biomarkers, Tissue biopsy
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 11, 2026, 8:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Pilot Study to Identify Biomarkers Associated With Chronic Traumatic Brain Injury

NCT01171131
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Blood/saliva sampling
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 11, 2026, 8:01 AM EDT
Active, not recruiting Not applicable Interventional Results available

Screening for Prostate Cancer in Older Patients (PLCO Screening Trial)

NCT00002540
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Laboratory Biomarker Analysis, Medical Examination Assessment, Screening Questionnaire Administration
Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
55 Years to 74 Years · Male only
Enrollment
76,685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 11, 2026, 8:01 AM EDT
Completed Not applicable Interventional Results available

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

NCT01701674
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Ipilimumab, Tumor Infiltrating Lymphocytes (TIL), Administration of Lymphodepletion, Cyclophosphamide as Part of Lymphodepletion, Fludarabine as Part of Lymphodepletion, High Dose IL-2, Adoptive Cell Therapy with TIL
Drug · Procedure · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 11, 2026, 8:01 AM EDT